New research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating encouraging results in addressing obesity and diabetes non-insulin-dependent condition. Animal data suggest a unique process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/